CollPlant Biotechnologies Ltd. (CLGN) reported its first quarter 2025 financial results and provided a comprehensive corporate update highlighting progress across its regenerative and aesthetic medicine pipeline.
The Israel-based company develops tissue regeneration and aesthetic products using its proprietary, non-animal recombinant human collagen or rhCollagen. Its platform supports applications in breast implants, dermal fillers, and bioinks for 3D bioprinting.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.